NasdaqGS:NTRABiotechs
Natera (NTRA) Is Up 20.3% After Raising 2026 Guidance And Expanding Signatera’s Oncology Reach
In early August 2026, Natera reported second-quarter revenue of US$752.75 million with higher testing volumes and narrower losses, raised full-year 2026 revenue guidance to US$2.85 billion–US$2.91 billion, and filed an US$849.22 million shelf registration for 3,200,000 common shares tied to an ESOP offering.
At the same time, Natera moved to deepen Signatera’s role in oncology by seeking Japanese approval of the test as a companion diagnostic in muscle-invasive bladder cancer, extending its...